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Introduction
What is the best strategy to approve
novel drugs for disease such as sleeping
sickness that predominantly affect patients
in Africa? How can African regulators best
be supported to evaluate these drugs for
their own populations? For many years,
African medicines regulatory authorities
(MRAs) have relied on stringent regulators
in developed countries to assess novel
pharmaceutical products such as drugs
and vaccines for use in African popula-
tions. However, a recent shift in the drug
product environment for Africa has put
this approach under strain. A score of new
products are now being, or have been,
developed specifically for diseases of the
developing world (Table 1), creating new
challenges for regulators in Africa and
elsewhere.
However, it is not at all certain that
African regulatory authorities currently
have the capacity to meet these new
demands. A study conducted by the World
Health Organization (WHO) in 2010
concluded that 90% of MRAs in sub-
Saharan Africa ‘‘were in a situation which
did not allow them to adequately carry out
regulatory functions,’’ and thus could not
guarantee the safety and efficacy of
medicines to be used in their country [1–
3]. While undoubtedly improving, growth
in African regulatory capacity is not
keeping up with these new challenges.
The growing demand to assess novel
neglected disease (ND) products for African
usehasgenerateda range ofresponsesfrom
policymakers and product developers, as
outlined below. While each approach offers
unique benefits, none is ideally suited as a
primary vehicle for drug registration for
Africa.Thereisalsonoguidancetoproduct
developers in choosing between approach-
es, and little or no integration between
approval mechanisms (see Figure 1). It is
now critical to review how novel ND drugs
are assessed and approved for African use.
This article is based on research conducted
for a report titled ‘‘Registering New Drugs:
The African Context’’ [4], commissioned
by the Drugs for Neglected Diseases
initiative (DNDi), and builds upon this
work with additional research and analysis.
Western Regulatory Approval
Routes
Historically, the majority of new ND
drugs have been first submitted to well-
established Western regulatory authorities
(e.g., United States Food and Drug
Administration [FDA], European Medi-
cines Agency [EMA], SwissMedic), either
for routine regulatory review or under
specific pathways such as Orphan Drug
legislation (ODL) or expedited approval
mechanisms. Multinational pharmaceuti-
cal companies and some Product Devel-
opment Partnerships (PDPs) have typically
used this approach because it offers clear
protocols and rules, liability management
and, in the case of ODL, tax breaks, free
scientific advice, and market exclusivities.
Firms also welcome the access Western
regulatory approval provides to early
commercial returns on products with
overlapping rich and poor markets.
While bringing decades of regulatory
experience to the table, use of Western
authorities to review ND drugs also has
drawbacks. It delays access for African
patients since African MRAs often wait for
the Western MRA decision before com-
mencing action, and it puts ND product
decisions in the hands of regulators who
have less experience in tropical disease
products, presentations, and epidemiolo-
gy, and who are not accountable for the
needs and safety of target African patients.
For instance, Western regulations may
omit data requirements vital for safe large-
scale use in Africa (e.g., trials assessing the
safe interaction of HIV and malaria
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(TB) drug registered under US Orphan
Drug provisions, ultimately could not be
used in African TB patients despite being
approved by the FDA because the trial
design excluded HIV-positive patients.
While HIV is less commonly associated
with TB in the US, it represents up to 70%
of TB patients in some sub-Saharan Africa
countries, making the efficacy data sub-
mitted to the FDA inadequate for use in
African populations [5]. Furthermore, the
relative risk-benefit of ND drugs can be
dramatically different in Africa and the
West, where analysis against the same
criteria can lead to completely different
conclusions. For example, the first rotavi-
rus vaccine, RotaShield, developed by
Wyeth-Ayerst and licensed by the FDA
in August 1998, was withdrawn from the
US market in October 1999 due to a one
in 10,000 risk of intussusception in chil-
dren. This precluded its subsequent intro-
duction in the developing world. While
this risk-benefit analysis may have been
valid for the US, where rotavirus causes
less than 60 deaths per year, the vaccine
was likely to have a much more favorable
risk-benefit ratio in Africa, where rotavirus
is responsible for approximately 5% of
deaths in children under the age of five (a
mortality rate of 183/100,000). Many of
these problems are heightened in the case
of regulatory pathways such as Orphan
Drug approval and FDA Accelerated
Review, which allow clinical trials to be
abridged or downsized in order to expe-
dite registration of treatments for diseases
that are rare and life-threatening in the
Western context (such as malaria), but
affect millions of patients in the developing
world.
Neglected Disease–Specific
Regulatory Pathways
Policymakers have responded to these
shortcomings by developing regulatory
pathways tailored for ND products, in-
cluding the EMA’s Article 58, WHO drug
prequalification, and FDA ‘‘tentative ap-
proval’’.
Article 58
Article 58, established by the European
Commission (EU) in 2004, aims to
facilitate and assist developing country
registration of medicines by providing the
same scientific assessment (‘‘opinion’’) on
products used outside the EU as for the
EU, but incorporates WHO in the review
process. Article 58’s strength lies in its
combination of stringent review stan-
dards, efficiency (average review time is
2.5 months), and structured input from
WHO disease experts from disease-en-
demic countries. However, it has fallen
victim to underutilization (only four
product applications have been submitted
since 2004), largely due to a lack of
incentives for product developers to use
this route. In particular, Article 58 does
not offer tax breaks or market exclusivi-
ties; does not result in European market-
ing approval; is not linked to Orphan
Drug approval; and does not formally
expedite approval through WHO drug
prequalification, although this may be
changing.
Summary Points
N A recent shift in the drug product environment for Africa has seen a score of
new products being developed specifically for diseases of the developing
world, creating new challenges for regulators in Africa and elsewhere. However,
it is not at all certain that African regulatory authorities currently have the
capacity to meet these new demands.
N The growing demand to assess novel neglected disease (ND) products for
African use has generated a range of responses from policymakers and product
developers, but there is limited guidance for product developers in choosing
between approaches, and little or no integration between approval mecha-
nisms.
N We discuss the various mechanisms in which novel ND drugs are assessed and
approved for developing country use, and put forth six recommendations to
create an efficient integrated system of national, regional, and international
approvals to achieve an optimal drug registration approach for Africa that can
reliably evaluate safety, efficacy, and quality of drugs for African use.
Table 1. Sample of novel neglected disease products presented to regulators since 2005 [8,11,12,20–23].
Novel Neglected Disease Products Regulatory Stage
Artesunate-amodiaquine ASAQ (malaria) Approved by 24 African countries
WHO prequalified (October 2008)
Artesunate-mefloquine ASMQ (malaria) Approved by Brazilian ANVISA (April 2008)
Coartem Dispersible (malaria) Approved by 14 African countries
Approved by Swissmedic (December 2008)
WHO prequalified (February 2009)
Intramuscular paromomycin (visceral leishmaniasis) Received FDA and EMA orphan drug designation (March 2005)
Approved by Drugs Controller General of India (August 2006)
Eurartesim (malaria) Submitted to EMA for approval (July 2009)
Moxifloxacin (TB) Clinical development plan submitted to developing country and/or Western regulators
PA-824 (TB) Clinical development plan submitted to developing country and/or Western regulators
Arterolane/PQP (malaria) Clinical development plan submitted to developing country and/or Western regulators
Azithromycin-chloroquine AZCQ (malaria) Clinical development plan submitted to developing country and/or Western regulators
Fexinidazole (sleeping sickness) Clinical development plan submitted to developing country and/or Western regulators
Additional source: correspondence with Novartis.
doi:10.1371/journal.pmed.1000411.t001
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Following the launch of the US Presi-
dent’s Emergency Plan for AIDS Relief
(PEPFAR), the FDA introduced expedited
approval in 2004 for HIV drugs purchased
with PEPFAR funds for use outside the
US. Seventy-one of the 100 products fully
or tentatively approved (products still
under patent in the US are given ‘‘tenta-
tive approval’’ until the patent expires) in
association with PEPFAR as of June 2009
were generic formulations of existing
drugs; 22 were new combinations or
regimens of existing drugs not previously
authorised in the US; and seven were
pediatric re-formulations. The approval
process is integrated with WHO prequal-
ification through the exchange of reviews
and the automatic inclusion of FDA-
reviewed drugs in the WHO prequalifica-
tion list: as of February 2010, 41% (113
drugs) of WHO prequalification drugs
were PEPFAR approvals [6,7]. While
helpful and efficient in assessing non-novel
HIV drugs associated with PEPFAR, this
program’s usefulness is limited by its
disease and product restrictions.
WHO Drug Prequalification
In 2001, the WHO began the drug
prequalification program as a ‘‘surrogate’’
regulatory approval mechanism on which
international procurement groups such as
the Global Fund to Fight AIDS, Tubercu-
losis and Malaria could rely while develop-
ing country capacity for drug regulation
was being strengthened. Evaluations are
conducted by mixed teams of developed
and developing country experts, with
around one-third of reviewers from Africa.
WHO prequalification has been relied
upon by African MRAs as a proxy for their
own drug assessments and approvals.
WHO prequalification focuses on only a
few diseases (in particular, HIV, malaria,
and TB), with the majority of approved
products being generic HIV drugs. As of
June 2009, the program had pre-qualified
280 drugs—86% for HIV (241), 7% for
TB (20), and 6% for malaria (16) (Figure 2).
Just over half (56%) of these were generics,
and 21% were new fixed-dose combina-
tions or formulations of existing drugs. A
further 23% were innovative drugs that
had been approved by a stringent MRA
prior to the WHO prequalification pro-
cess.
WHO prequalification (in tandem with
FDA tentative approval) has vastly accel-
erated African access to HIV, and to a
lesser degree, malaria products; neverthe-
less, it could be further optimized. It
covers only a few of the major diseases of
Africa, and does not include a review of
novel ND products. Due to its voluntary,
no-fee, capacity-building approach, WHO
prequalification can be slow (averaging 2
years) and it would benefit from more
seamless integration with product reviews
by stringent MRAs.
Alternative Approval Strategies
In response to the drawbacks of both
standard and ND-specific regulatory re-
view, product developers have begun
exploring alternatives, some of which offer
insights for drug registration in Africa.
Parallel approvals have been a common
strategy for many PDPs, with dossiers
submitted simultaneously to Western and
developing country MRAs. The aim is to
achieve high regulatory standards while
expediting African registration. In prac-
tice, however, time gains are often illusory,
as most African MRAs wait on WHO or
Western approval before commencing
their own process. Parallel approval also
fails to assist or build the regulatory
capacity of African MRAs.
Another potential strategy is twinned
review, under which developing country
regulators assess a pharmaceutical dossier
in consultation with, or alongside, revie-
wers from stringent regulatory agencies.
Twinned reviews can offer a potentially
Figure 1. Neglected disease drug registration timeline [7,9,11–19]. Additional source: correspondence with Novartis.
doi:10.1371/journal.pmed.1000411.g001
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experience in product assessment with
developing country expertise on endemic
diseases, while expediting African regula-
tory approval and leaving risk-benefit
analysis and decisions to MRAs responsible
for areas where products will be used. More
importantly, twinned review can build
African MRA capacity through first-hand
training for developing country regulators
by Western regulatory experts. Neverthe-
less, there has not yet been a formal
twinned regulatory review of any new ND
product, although in 2008 the WHO
organized a joint ‘‘practice’’ review of the
artesunate-amodiaquine (ASAQ) dossier
developed by the DNDi and involving
regulators from African MRAs and the
EMA. The implementation of twinned
reviews will require resources and commit-
ment by both Western and developing
country regulators to move forward, but
early stage joint reviews, such as those
facilitated by the WHO with The Gambia,
Mali, Ghana, and Senegal for the clinical
trial application of the PATH Meningitis
Vaccine Program’s conjugate vaccine, are
certainly a step in the right direction.
Product developers can also seek first
approval from developing country MRAs
without seeking prior, parallel, or twinned
approval by WHO prequalification or a
stringent regulatory agency. Used primar-
ily by PDPs or developing country man-
ufacturers, this option offers rapid access
for domestic populations. For example,
artesunate-mefloquine (ASMQ), devel-
oped by DNDi and Brazil’s Farminguin-
hos/Fiocruz, was first registered in Brazil
in April 2008 [8], and is currently under
assessment by the WHO prequalification
program. ASAQ, jointly developed by
DNDi and Sanofi-Aventis, was first regis-
tered by the Moroccan regulatory author-
ity in February 2007 and then received
WHO prequalification in October 2008
[9], and the Institute for One World
Health first registered intramuscular par-
omomycin for the treatment of visceral
leishmaniasis in India in August 2006 [5].
Discussion
An optimal drug registration approach
for Africa should reliably evaluate safety,
efficacy, and quality of drugs for African use.
It should include African expertise, contrib-
ute to building African regulatory capacity,
and, ultimately, expedite African access by
reducing duplicative and sequential reviews
by different regulators. However, as the
above overview shows, the current system of
ND drug approval is still far from achieving
these goals. It is often inefficient, uses
regulatory resources wastefully, and creates
lengthy delays for patient access. Capacity-
building opportunities for African regulators
are routinely lost and, in the worst case,
regulatory processes and decisions may not
meet Africa’s needs for the best, safest, and
most appropriate drugs.
The following proposals are aimed at
rapidly moving the current regulatory
paradigm to the optimal scenario:
1. Institute formal twinned regulatory
review; that is, any review of a novel
ND product by a stringent MRA (or
WHO prequalification) should formal-
ly include regulators from relevant
endemic countries.
2. Automatic WHO prequalification of all
novel ND products approved by strin-
gent MRAs using standard regulatory
pathways, and which meet WHO
treatment recommendations. (With
the exception of approvals under the
Accelerated approval (FDA)/Condi-
tional approval (EMA) mechanisms.
Approvals under ODL should be
reviewed on a case-by-case basis.)
3. Itegrate Article 58 with other approval
mechanisms by allowing automatic
WHO drug prequalification for prod-
ucts given a positive opinion under
Article 58; AND allow positive Article
Figure 2. WHO prequalified drugs by disease [7].
doi:10.1371/journal.pmed.1000411.g002
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market access either by conversion to
EMA approval with a single European
bridging study; OR link to automatic
EU Orphan approval, which would
additionally provide eligibility for tax
breaks and market exclusivities.
4. Select experienced Western MRAs to
conduct prequalifications on behalf of,
and in addition to, the WHO.
5. Conduct a strategic review of WHO
drug prequalification disease and prod-
uct priorities, along the lines of WHO
Strategic Advisory Group of Experts
(SAGE) reviews for vaccines (estab-
lished by the Director-General of the
World Health Organization in 1999 to
provide guidance on the work of the
WHO Immunization, Vaccines and
Biologicals Department), to identify
additional priority diseases or products
to be addressed by WHO prequalifica-
tion (and/or outsourced to reference
MRAs for prequalification).
6. Fund Centres of Regulatory Excellence
in each of Africa’s main regions that
would conduct:
# Joint review of product dossiers for
the region (with external support as
necessary).
# Joint good manufacturing practices
plant inspections for the region.
# Clinical trial regulation, including
joint regional review/approval.
# ‘‘Twinned’’ reviews i.e., formal partic-
ipation in external regulatory reviews
such as FDA reviews, Article 58
assessments, or WHO prequalification.
# Training and regulatory fellowships,
including attachments to stringent
external regulators and time with
their national regulatory authority.
Collectively, these measures would
improve the quality of ND drug reviews
for the targeted populations; create an
efficient integrated system of national,
regional, and international approvals;
expand the scope of regulatory support
for Africa to include many more diseases
and products; provide an institutional
pathway to train and retain African
regulators; and build African capacity to
manage its own regulatory tasks. To move
these ideas forward, it will be up to key
policymakers in Africa and donor coun-
tries, funders of ND research and devel-
opment, innovators, and, more impor-
tantly, regulatory agencies to reach a
consensus on how these can be best
implemented to ultimately benefit pa-
tients. The WHO, as a credible and
trusted multilateral agency, can potential-
ly play a large role in leading these efforts,
as seen in recent pan-African initiatives
such as the African Network for Drugs &
Diagnostics Innovation [10].
In the face of scarce regulatory re-
sources and large gaps in capacity, these
proposals could address the immediate
need for efficient, appropriate regulatory
approval of new ND products, while
building a sustained and independent
African regulatory infrastructure in a
way that truly addresses African needs
and realities.
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